X4 Pharmaceuticals
XFORXFOR · Stock Price
Historical price data
Overview
X4 Pharmaceuticals, founded in 2015, is a Boston-based biotech with a mission of 'Rare Resolve' to develop and commercialize therapies for rare immune diseases. The company achieved a pivotal milestone with the April 2024 FDA approval and subsequent U.S. launch of XOLREMDI® for WHIM syndrome, validating its CXCR4 platform. Its strategy is to build a sustainable commercial foundation in WHIM syndrome while aggressively pursuing label expansion into chronic neutropenic disorders through a pivotal Phase 3 trial, supported by strategic ex-U.S. partnerships.
Technology Platform
Proprietary expertise in the CXCR4/CXCL12 pathway, focused on developing oral small-molecule antagonists to mobilize white blood cells from bone marrow for treating rare immune deficiencies.
Pipeline
11| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Mavorixafor + Placebo | Neutropenia | Phase 3 | |
| Mavorixafor + Placebo | WHIM Syndrome | Phase 3 | |
| X4P-001 | WHIM Syndrome | Phase 2 | |
| Mavorixafor | Neutropenia | Phase 1/2 | |
| X4P-001 + Nivolumab | Clear Cell Renal Cell Carcinoma | Phase 1/2 |
FDA Approved Drugs
1Opportunities
Risk Factors
Competitive Landscape
In WHIM syndrome, X4 faces no direct drug competition as the first approved therapy. In chronic neutropenia, the main competitor is injectable granulocyte colony-stimulating factor (G-CSF), where mavorixafor's oral dosing offers a potential quality-of-life advantage. No other late-stage oral CXCR4 antagonists are targeting this specific rare disease space.
